Patent rejected for MNC’s cancer drug, generics to follow
The Indian Patent Office has rejected AbbVie's patent application for its cancer drug Venetoclax, citing a lack of inventive step and no enhancement in therapeutic efficacy. This decision, if upheld, could allow for the entry of more affordable generic versions of the drug into the Indian market.
The Indian Patent Office has rejected AbbVie's patent application for its cancer drug Venetoclax, citing a lack of inventive step and no enhancement in therapeutic efficacy. This decision, if upheld, could allow for the entry of more affordable generic versions of the drug into the Indian market.
